Sender Company & Partners’s Nautilus Biotechnolgy NAUT Stock Holding History

Sender Company & Partners’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-73,960	Closed	-$321K	–	48
2022 Q1	$321K	Sell	73,960 -69,375	-48%	-$285K	0.34%	40
2021 Q4	$742K	Buy	+143,335	New	+$767K	0.38%	66

Other funds holding NAUT

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Sender Company & Partners's NAUT Position: Q2 2022 in Review

Sender Company & Partners sold out of Nautilus Biotechnolgy (NAUT) in Q2 2022, closing a stake of 73,960 shares — an estimated $321K sold.

Sender Company & Partners first reported a position in NAUT in Q4 2021 and held it in 2 quarters. The position peaked at $742K in Q4 2021. 83 funds tracked by Wall St. Rank hold NAUT as of Q2 2022.

Sender Company & Partners reported no remaining Nautilus Biotechnolgy position as of Q2 2022 after selling out during the quarter.
Sender Company & Partners sold 73,960 Nautilus Biotechnolgy shares in Q2 2022, an estimated $321K.
Sender Company & Partners first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 2 quarters.
Sender Company & Partners's Nautilus Biotechnolgy position peaked at $742K in Q4 2021.
83 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2022.

Based on Sender Company & Partners's 13F filing for Q2 2022, filed 12 Aug 2022.